SEC Form 4 · accession 0001209191-17-042569
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Booth
Director
Period of report
Jun 28, 2017
Accepted (ET)
Jun 30, 2017 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $12.06 | Jun 28, 2017 | A | 12,000 | A | — | Jun 27, 2027 | Common Stock | 12,000 | 12,000 | D |
| Stock Option (right to buy)F4,F2,F3 | $12.00 | holding | — | — | — | — | Mar 23, 2027 | Common Stock | 6,727 | 6,727 | D |
Explanation of responses
- F1Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
- F2This option was granted to Bruce Booth, Ph.D., a director of the Issuer. The proceeds of any sale of shares of common stock issued to Dr. Booth upon exercise of this option will be transferred to Atlas Venture Advisors, Inc. and therefore Dr. Booth disclaims beneficial ownership of such shares, which belongs to Atlas Venture Advisors, Inc.
- F3Previously reported grant to the Reporting Person of a stock option under the Plan. The shares vest in three equal quarterly installments beginning on April 1, 2017 through December 31, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The option expires 10 years after the date of grant.
- F4Represents the corrected number of derivative securities beneficially owned pursuant to a stock option granted to the Reporting Person on March 24, 2017, as previously reported on a Form 4 filed with the Securities and Exchange Commission on March 28, 2017. The adjustment is due to a change in the final closing price of the Issuer's shares as reported on The NASDAQ Capital Market on the date of grant.